# A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer

> **NCT07649928** · EARLY_PHASE1 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** ES502 Injection

## Key facts

- **NCT ID:** NCT07649928
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-18
- **Primary completion:** 2028-12
- **Final completion:** 2029-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649928, "A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*